Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature

Niesert, Anne‐Charlotte; Guertler, Anne; Schutti, Olga; Engels, Laura; Flaig, Michael J.; French, Lars E.; Schlaak, Max; Reinholz, Markus

doi:10.2340/00015555-3840

Cited by 9 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LP is a chronic, immune‐mediated, inflammatory disease affecting the skin, nails, eyes, mucous membranes, and urinary tract 17 . Drug‐induced LP has been associated with various agents including antimalarials, NSAIDs, beta‐blockers, thiazide diuretics, and in recent years, PD‐1 inhibitors 18 . Shi et al 19 reported that of 17 patients who underwent biopsy for bullous lesions following PD‐1 inhibitor therapy, 16 had features of lichenoid interface dermatitis, suggesting that there is a distinct cutaneous lichenoid eruption associated with anti‐programmed cell death 1 therapy 19 …”

Section: Discussionmentioning

confidence: 99%

“…17 Druginduced LP has been associated with various agents including antimalarials, NSAIDs, beta-blockers, thiazide diuretics, and in recent years, PD-1 inhibitors. 18 Shi et al 19 reported that of 17 patients who underwent biopsy for bullous lesions following PD-1 inhibitor therapy, 16 had features of lichenoid interface dermatitis, suggesting that there is a distinct cutaneous lichenoid eruption associated with antiprogrammed cell death 1 therapy. 19 A review of multiple cases reporting LP following PD-1 inhibitor therapy found malignant melanoma and NSCLC to be the leading malignancies for starting PD-1 inhibitors.…”

Section: Lichenoid Dermatoses In Association With Pd-1 Inhibitor Therapymentioning

confidence: 99%

See 1 more Smart Citation

Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab

Shah

Bhate

Hernandez

2022

Dermatologic Therapy

View full text Add to dashboard Cite

The widespread use of PD-1 inhibitors to treat various solid tumors has brought certain challenges for the clinician, including immune-related adverse events (irAEs).Cutaneous toxicities are among the most observed irAEs. Bullous and lichenoid dermatoses following PD-1 inhibitor therapy have been described. Here we report a novel case of lichen planus pemphigoides, featuring characteristics of both bullous pemphigoid and lichen planus, in a patient treated with nivolumab for renal cell carcinoma. We subsequently review all three cutaneous conditions which may arise in the context of PD-1 inhibitor therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Lichenoid Dermatoses In Association With Pd-1 Inhibitor Therapymentioning

confidence: 99%

Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab

Shah

Bhate

Hernandez

2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Histologically, CD163+ M2 macrophages are prominent in the lesional skin of bullous pemphigoid [ 65 ], and soluble (s)CD163 is increased in serum from patients with bullous pemphigoid compared to healthy donors [ 66 ]. Notably, CD163+ tumor-associated macrophages (TAMs) in melanoma express both PD1 and PD-L1, and blockade of PD-L1/PD1 signals by anti-PD1 Abs activates TAMs [ 67 , 68 ], leading to the production of TAM-activating factors such as sCD163 and chemokines in the serum of melanoma patients [ 57 ]. In addition, serum levels of sCD163 were significantly correlated with the efficacy of anti-PD1 Abs [ 57 ].…”

Section: Adverse Events Of Icismentioning

confidence: 99%

“…Notably, CD163+ tumor-associated macrophages (TAMs) in melanoma express both PD1 and PD-L1, and blockade of PD-L1/PD1 signals by anti-PD1 Abs activates TAMs [ 67 , 68 ], leading to the production of TAM-activating factors such as sCD163 and chemokines in the serum of melanoma patients [ 57 ]. In addition, serum levels of sCD163 were significantly correlated with the efficacy of anti-PD1 Abs [ 57 ]. Thus, bullous pemphigoid-like cutaneous irAEs caused by anti-PD1/PD-L1 Abs might correlate with the prognosis of advanced melanoma.…”

Section: Adverse Events Of Icismentioning

confidence: 99%

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Fujimura

Muto

Asano

2022

IJMS

View full text Add to dashboard Cite

Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have been recognized as anchor drugs for treating advanced melanoma, with or without additional combination drugs such as ipilimumab, but the efficacies of these immunotherapies are not fully satisfactory. In this review, we describe the development of the currently available anti-PD1 Abs-based immunotherapies for advanced melanoma, focusing on their efficacy and immune-related adverse events (AEs), as well as clinical trials still ongoing for the future treatment of advanced melanoma.

show abstract

“… 25 Nail involvement presenting with subungual hyperkeratosis, dystrophy, and ridging has been reported. Rare phenotypes such as hyperkeratotic LP, 27 , 28 bullous LP, 29–31 and lichen nitidus 32 have been observed. Bullous LP is commonly seen on the lower extremities.…”

Section: Various Mucocutaneous Disordersmentioning

confidence: 99%

Skin Manifestation Induced by Immune Checkpoint Inhibitors

Yamamoto¹

2022

CCID

View full text Add to dashboard Cite

In accordance with recent therapeutic progress of immune checkpoint inhibitors for certain cancers, various disorders are induced as immune-related adverse events (irAEs) affecting the skin, gut, thyroid gland, lung, and liver. Among such irAEs, mucocutaneous manifestation is the most common. Cutaneous manifestations are categorized into several groups, ie, inflammatory reactions, immunobullous reactions, alterations of epidermal keratinocytes, and alterations of epidermal melanocytes; however, there are additionally various cutaneous toxicities, unclassified into those groups. Blocking of programmed cell death 1 (PD-1)/programmed cell death ligand 1(PDL1) can lead to the induction of autoimmune reaction, via activation of cytotoxic T cells, inhibition of regulatory T cell function, and alteration of cytokine balance. Similarly, blockade of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) reduces the suppressive function of regulatory T cells. Due to those mechanisms, various autoimmune conditions can be induced, in addition to nonspecific drug eruptions. Dermatologists should be aware of various types of those mucocutaneous manifestations, either common or rare, as well as the management of such conditions. Herein, various mucocutaneous manifestations of irAEs and cases involving Japanese patients have been described, based on a single institute’s experience.

show abstract

Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature

Cited by 9 publications

References 11 publications

Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab

Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

Skin Manifestation Induced by Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About